This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
A systematic review on the efficacy and safety of transcatheter device closure of ventricular septal defects (VSD)
The researchers performed a systematic review to look at outcomes and complications associated with transcatheter closure of ventricular septal defects (VSD). This analysis suggests that transcatheter device closure of VSD is safe and yields good results. The limitations of this study are difficulties in analyzing different devices individually, and segregating the different VSD types, Further stratification by type of VSD, age of patients, and prevention of complications is needed before this can be recommended for routine treatment.
- A PubMed search for series in English on device closure of VSD from 2003 to June 2012 was performed.
- They excluded small series that were included in multicenter studies and patients who had acquired VSD following myocardial infarction.
- The random effects model was used to obtain pooled estimates of success and complications.
- A total of 37 publications comprising 4,406 patients with VSD (perimembranous=3,758, muscular=419, intracristal=47, doubly committed subarterial=36, multiple=16, postsurgical=123, unclassified=7) were included in this analysis.
- The age of patients ranged from 3 days to 84 years.
- The pooled estimate of successful device implantation was 96.6% (95% CI: 95.7-97.5).
- The most common complication is residual shunt (pooled estimated 25.5%; 95% CI: 18.9-32.1).
- Others included valvular defects (pooled estimate 4.9%; 95% CI: 3.4–6.4) and arrhythmias (pooled estimate 10.6%; 95% CI: 8.4-12.7).